Mednet Logo

Is switching to carboplatin/gemcitabine reasonable for a patient with muscle invasive bladder CA who proceeded to cystectomy first and had AKI with cisplatin/gemcitabine prohibiting further cisplatin?

If not carboplatin, would you recommend nivolumab instead?
2 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of North Carolina at Chapel Hill
Answered on

There is not a role for gemcitabine and carboplatin in the adjuvant setting in patients with muscle invasive bladder cancer. Based on CheckMate 274 (Bajorin et al., PMID 34077643), in patients with MIBC with a high risk of recurrence (pT3, pT4a, or pN+ and not eligible for or declined adjuvant cispl...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · AdventHealth Cancer Institute
Answered on

In a patient who never received neoadjuvant chemotherapy and started adjuvant Gem/Cis or dose dense MVAC but developed AKI during adjuvant chemo- I agree that there is no data for switching to carboplatin-gemcitabine. There is also no data for switching to nivolumab in such patients. However, this s...

Join for free or sign in to see the full answer